Traders sold shares of Stryker Corporation (NYSE:SYK) on strength during trading hours on Thursday. $42.87 million flowed into the stock on the tick-up and $298.55 million flowed out of the stock on the tick-down, for a money net flow of $255.68 million out of the stock. Of all companies tracked, Stryker had the 0th highest net out-flow for the day. Stryker traded up $1.90 for the day and closed at $156.00

A number of research firms have recently commented on SYK. SunTrust Banks reaffirmed a “buy” rating and set a $161.00 target price on shares of Stryker in a research note on Monday, October 2nd. Oppenheimer set a $156.00 target price on Stryker and gave the company a “hold” rating in a research note on Monday, October 30th. Canaccord Genuity upped their target price on Stryker from $155.00 to $162.00 and gave the company a “buy” rating in a research note on Friday, October 27th. Zacks Investment Research cut Stryker from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, Cowen set a $160.00 target price on Stryker and gave the company a “buy” rating in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $152.10.

The firm has a market cap of $58,381.07, a P/E ratio of 24.72, a PEG ratio of 2.46 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.02. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The company had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the prior year, the firm earned $1.39 earnings per share. Stryker’s revenue was up 6.1% compared to the same quarter last year. research analysts expect that Stryker Corporation will post 6.47 EPS for the current year.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the transaction, the insider now owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 7.40% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Stryker by 2.8% during the second quarter. Vanguard Group Inc. now owns 24,078,709 shares of the medical technology company’s stock worth $3,341,643,000 after buying an additional 657,656 shares during the period. BlackRock Inc. lifted its holdings in Stryker by 5.2% during the second quarter. BlackRock Inc. now owns 23,115,853 shares of the medical technology company’s stock worth $3,208,017,000 after buying an additional 1,139,082 shares during the period. Jensen Investment Management Inc. lifted its holdings in Stryker by 11.3% during the third quarter. Jensen Investment Management Inc. now owns 2,472,476 shares of the medical technology company’s stock worth $351,141,000 after buying an additional 251,685 shares during the period. Legal & General Group Plc lifted its holdings in Stryker by 2.8% during the third quarter. Legal & General Group Plc now owns 1,805,572 shares of the medical technology company’s stock worth $256,393,000 after buying an additional 49,143 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in Stryker by 4.8% during the third quarter. Wells Fargo & Company MN now owns 1,742,959 shares of the medical technology company’s stock worth $247,536,000 after buying an additional 79,551 shares during the period. 74.97% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/02/traders-sell-shares-of-stryker-syk-on-strength-syk.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.